Top Midday Decliners

MT Newswires Live12-11

CervoMed (CRVO) said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.

Shares slumped 77% as intraday trading volume soared to over 6.44 million from a daily average of about 122,000.

MEDIROM Healthcare Technologies (MRM) shares tumbled 45% amid heavy trading after the company unveiled late Monday an offering of 2.86 million American Depositary Shares at $1.75 each, targeting gross proceeds of about $5 million.

More than 1.51 million shares traded intraday compared with a daily average of about 117,000.

Biora Therapeutics (BIOR) said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement.

Shares sank 60%, with intraday trading volume at over 1.39 million versus a daily average of about 88,000.

Price: 2.36, Change: -7.89, Percent Change: -76.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490604173?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-11 02:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490604173","market":"sh","top_or_hot":-1,"title":"Top Midday Decliners","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CRVO\">CervoMed</a> (CRVO) said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.</p><p>Shares slumped 77% as intraday trading volume soared to over 6.44 million from a daily average of about 122,000.</p><p>MEDIROM Healthcare Technologies (MRM) shares tumbled 45% amid heavy trading after the company unveiled late Monday an offering of 2.86 million American Depositary Shares at $1.75 each, targeting gross proceeds of about $5 million.</p><p>More than 1.51 million shares traded intraday compared with a daily average of about 117,000.</p><p>Biora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BIOR) said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement.</p><p>Shares sank 60%, with intraday trading volume at over 1.39 million versus a daily average of about 88,000.</p><p>Price: 2.36, Change: -7.89, Percent Change: -76.98</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Decliners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Decliners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-11 02:14 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CervoMed (CRVO) said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.Shares slumped 77% as ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490604173","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490604173","pubTimestamp":1733854462,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CervoMed  said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.Shares slumped 77% as intraday trading volume soared to over 6.44 million from a daily average of about 122,000.MEDIROM Healthcare Technologies  shares tumbled 45% amid heavy trading after the company unveiled late Monday an offering of 2.86 million American Depositary Shares at $1.75 each, targeting gross proceeds of about $5 million.More than 1.51 million shares traded intraday compared with a daily average of about 117,000.Biora Therapeutics  said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement.Shares sank 60%, with intraday trading volume at over 1.39 million versus a daily average of about 88,000.Price: 2.36, Change: -7.89, Percent Change: -76.98","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BIOR":"Biora Therapeutics, Inc.","MRM.AU":"MMA OFFSHORE LTD","CRVO":"CervoMed","BK4196":"保健护理服务","BK7108":"石油天然气设备与服务","BK4192":"特殊消费者服务","MRM":"MEDIROM Healthcare Technologies, Inc."},"translate_title":"午盘跌幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRM.AU":1,"BIOR":0.9,"CRVO":0.9,"MRM":0.9},"content_text":"CervoMed (CRVO) said Tuesday that a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.Shares slumped 77% as intraday trading volume soared to over 6.44 million from a daily average of about 122,000.MEDIROM Healthcare Technologies (MRM) shares tumbled 45% amid heavy trading after the company unveiled late Monday an offering of 2.86 million American Depositary Shares at $1.75 each, targeting gross proceeds of about $5 million.More than 1.51 million shares traded intraday compared with a daily average of about 117,000.Biora Therapeutics (BIOR) said in a regulatory filing Tuesday that Nasdaq has determined to delist its securities for failing to comply with the market value of listed securities requirement.Shares sank 60%, with intraday trading volume at over 1.39 million versus a daily average of about 88,000.Price: 2.36, Change: -7.89, Percent Change: -76.98","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490604173"}